These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6290849)

  • 41. Evidence for different receptor sites in mouse spleen cells for the Sendai virus hemagglutinin-neuraminidase (HN) and fusion (F) glycoproteins.
    Peterhans E; Baechi T; Yewdell J
    Virology; 1983 Jul; 128(2):366-76. PubMed ID: 6310862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid.
    Chengalvala MV; Bhat RA; Bhat BM; Vernon SK; Lubeck MD
    Vaccine; 1999 Mar; 17(9-10):1035-41. PubMed ID: 10195612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of lipid composition upon fusion of liposomes with Sendai virus membranes.
    Haywood AM; Boyer BP
    Biochemistry; 1984 Aug; 23(18):4161-6. PubMed ID: 6091739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cell type specific expression of pre S 1 antigen and secretion of hepatitis B virus surface antigen. Brief Report.
    Marquardt O; Heermann KH; Seifer M; Gerlich WH
    Arch Virol; 1987; 96(3-4):249-56. PubMed ID: 3662826
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sendai virus-mediated lysis of liposomes requires cholesterol.
    Kundrot CE; Spangler EA; Kendall DA; MacDonald RC; MacDonald RI
    Proc Natl Acad Sci U S A; 1983 Mar; 80(6):1608-12. PubMed ID: 6300860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic hepatitis B infection in adolescents who received primary infantile vaccination.
    Wu TW; Lin HH; Wang LY
    Hepatology; 2013 Jan; 57(1):37-45. PubMed ID: 22858989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell fusion by the antigen-antibody complex of Sendai virus studied by electron microscopy.
    Hosaka Y; Shimizu YK
    J Gen Virol; 1974 Aug; 24(2):369-74. PubMed ID: 4368476
    [No Abstract]   [Full Text] [Related]  

  • 48. Membrane structure of the hepatitis B virus surface antigen particle.
    Satoh O; Imai H; Yoneyama T; Miyamura T; Utsumi H; Inoue K; Umeda M
    J Biochem; 2000 Apr; 127(4):543-50. PubMed ID: 10739944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ongoing murine T1 or T2 immune responses to the hepatitis B surface antigen are excluded from the liver that expresses transgene-encoded hepatitis B surface antigen.
    Schirmbeck R; Wild J; Stober D; Blum HE; Chisari FV; Geissler M; Reimann J
    J Immunol; 2000 Apr; 164(8):4235-43. PubMed ID: 10754320
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines.
    Heijtink RA; van Bergen P; Paulij WP; de Man RA; Osterhaus AD
    Vaccine; 2000 Feb; 18(15):1531-8. PubMed ID: 10618551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.
    Desombere I; Willems A; Gijbels Y; Leroux-Roels G
    J Virol; 2006 Apr; 80(7):3506-14. PubMed ID: 16537618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incorporation of hepatitis-B surface antigen (HBsAg) into liposomes.
    Manesis EK; Cameron CH; Gregoriadis G
    Biochem Soc Trans; 1978; 6(5):925-8. PubMed ID: 744347
    [No Abstract]   [Full Text] [Related]  

  • 53. Mutated epitopes of hepatitis B surface antigen fused to the core antigen of the virus induce antibodies that react with the native surface antigen.
    Shiau AL; Murray K
    J Med Virol; 1997 Mar; 51(3):159-66. PubMed ID: 9139078
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of the alternative pathway of guinea pig complement by Sendai virus-treated cells.
    Okada N; Shibuta H; Okada H
    Microbiol Immunol; 1979; 23(7):689-92. PubMed ID: 228167
    [No Abstract]   [Full Text] [Related]  

  • 55. In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients.
    Barnaba V; Levrero M; Ruberti G; van Dyke A; Perrone A; Musca A; Balsano F
    Clin Exp Immunol; 1987 Nov; 70(2):283-8. PubMed ID: 2962789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg).
    Golsaz-Shirazi F; Amiri MM; Farid S; Bahadori M; Bohne F; Altstetter S; Wolff L; Kazemi T; Khoshnoodi J; Hojjat-Farsangi M; Chudy M; Jeddi-Tehrani M; Protzer U; Shokri F
    Antiviral Res; 2017 Aug; 144():153-163. PubMed ID: 28641998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fusion of Sendai virus with liposomes: dependence on the viral fusion protein (F) and the lipid composition of liposomes.
    Hsu MC; Scheid A; Choppin PW
    Virology; 1983 Apr; 126(1):361-9. PubMed ID: 6302992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Membrane-bound antiviral antibodies as receptors for Sendai virions in receptor-depleted erythrocytes.
    Nussbaum O; Zakai N; Loyter A
    Virology; 1984 Oct; 138(2):185-97. PubMed ID: 6093364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES.
    Kim SJ; Suh D; Park SE; Park JS; Byun HM; Lee C; Lee SY; Kim I; Oh YK
    Virology; 2003 Sep; 314(1):84-91. PubMed ID: 14517062
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis B surface antigen circulating immune complexes (HBsAg-CICs) in patients with bleeding disorders.
    Anh-Tuan N; Novák E; Hollán SR
    Vox Sang; 1981 Jan; 40(1):12-6. PubMed ID: 6971526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.